Command Palette

Search for a command to run...

Clinical Trials · NCT01784965

Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Stanford University
Enrollment
69
Start date
Dec 2009
Locations
See registry
Primary endpoint
Change in Weight Reported at 14 Weeks
View Liraglutide compound reference